ClinicaliQ Trial Snapshot
- A Study of JNJ-88549968 for the Treatment of Calreticulin (CALR)-Mutated Myeloproliferative Neoplasms — Recruiting • Phase I • Oncology • NCT06150157.
- Drug Being Tested: JNJ-88549968, a novel therapeutic agent targeting CALR-mutated myeloproliferative neoplasms (MPNs), with the study establishing safety profile, recommended phase 2 dose, and optimal dosing schedules through dose escalation and expansion phases.
- Patient Eligibility Overview: Adults with confirmed CALR-mutated MPNs (including essential thrombocythemia, polycythemia vera, or primary myelofibrosis) who meet defined haematological and organ function criteria, excluding those with prior or active malignancies or significant comorbidities.
Use This Page For
- Quick orientation before opening the registry record.
- Checking recruitment status, phase and sponsor at a glance.
- Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying
The purpose of this study is to characterize safety and to determine the Recommended Phase 2 Dose (RP2D[s]) and optimal dosing schedule(s) of JNJ-88549968 in part 1 (Dose Escalation); to characterize the safety of JNJ- 88549968 at RP2D(s) in part 2 (Cohort Expansion). For U.S. sites: the purpose of this study is to characterize the safety and to determine the RP2D(s) and optimal dosing schedule(s) of JNJ-88549968 in Part 1 and part 1b (Dose Escalation), and to characterize the safety of JNJ-88549968 at the RP2D(s) in Part 2 and part…
Eligibility Snapshot
- : * Be greater than or equal to (>=) 18 years of age (or the legal age of majority in the jurisdiction in which the study is taking place, whichever the greater) at the time of informed consent * Positive for a calreticulin (CALR) driver mutation of essential thrombocythemia (ET) or myelofibrosis (MF) * Participants with ET and MF with risk characteristics as described in the protocol * Have an Eastern Cooperative Oncology Group (ECOG) performance status grade of less than or equal to (
Use the source registry for the full inclusion and exclusion criteria before discussing referral or enrolment.